DOCSLIB.ORG

Growth Hormone, IGF-I and Insulin and Their Abuse in Sport

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Growth Hormone, IGF-I and Insulin and Their Abuse in Sport British Journal of Pharmacology (2008) 154, 542–556 & 2008 Nature Publishing Group All rights reserved 0007– 1188/08 $30.00 www.brjpharmacol.org REVIEW Growth hormone, IGF-I and insulin and their abuse in sport RIG Holt and PH So¨nksen Principal Investigators GH-2004 Project, Endocrinology and Metabolism Sub-Division, Developmental Origins of Adult Health and Disease Division, School of Medicine, University of Southampton, Southampton, UK There is widespread anecdotal evidence that growth hormone (GH) is used by athletes for its anabolic and lipolytic properties. Although there is little evidence that GH improves performance in young healthy adults, randomized controlled studies carried out so far are inadequately designed to demonstrate this, not least because GH is often abused in combination with anabolic steroids and insulin. Some of the anabolic actions of GH are mediated through the generation of insulin-like growth factor-I (IGF-I), and it is believed that this is also being abused. Athletes are exposing themselves to potential harm by self- administering large doses of GH, IGF-I and insulin. The effects of excess GH are exemplified by acromegaly. IGF-I may mediate and cause some of these changes, but in addition, IGF-I may lead to profound hypoglycaemia, as indeed can insulin. Although GH is on the World Anti-doping Agency list of banned substances, the detection of abuse with GH is challenging. Two approaches have been developed to detect GH abuse. The first is based on an assessment of the effect of exogenous recombinant human GH on pituitary GH isoforms and the second is based on the measurement of markers of GH action. As a result, GH abuse can be detected with reasonable sensitivity and specificity. Testing for IGF-I and insulin is in its infancy, but the measurement of markers of GH action may also detect IGF-I usage, while urine mass spectroscopy has begun to identify the use of insulin analogues. British Journal of Pharmacology (2008) 154, 542–556; doi:10.1038/bjp.2008.99; published online 31 March 2008 Keywords: GH; IGF-I; insulin; sport; abuse Abbreviations: FFA, free fatty acid; GH, growth hormone; IGF-I, insulin-like growth factor-I; IGFBP, IGF binding protein; P-III-P, type 3 pro-collagen; rhGH, recombinant human growth hormone Introduction It is widely believed that growth hormone (GH) has been from anabolic steroids and therefore it seems likely that their used by sportsmen and women since the 1980s to improve effects will be additive. This has led many athletes to their athletic performance (McHugh et al., 2005) despite combine GH with insulin and anabolic steroids (So¨nksen, being banned for many years and appearing on the World 2001). Anti-Doping Agency list of banned substances. The GH doses used by athletes are thought to be up to 10 The actions of GH that interest athletes are anabolic and times higher than those used by endocrinologists, and as lipolytic, leading to an increase in lean body mass and such athletes are putting themselves at risk of harmful effects reduction in fat mass. Some of the anabolic GH actions are such as hypertension, diabetes and Creutzfeld–Jakob disease. mediated through the generation of insulin-like growth The detection of GH poses the greatest contemporary factor-I (IGF-I), and there is anecdotal evidence that this too challenge to the anti-doping community. The detection of is being abused by athletes either alone or in combination GH abuse has proved difficult for several reasons. Unlike with GH. The regulation of protein synthesis involves the many substances of abuse, such as synthetic anabolic synergistic actions of GH and IGF-I stimulating protein steroids, GH is a naturally occurring substance. The demon- synthesis, while insulin simultaneously inhibits protein stration of exogenous administration must therefore rely on breakdown (Russell Jones et al., 1993). GH stimulates protein finding concentrations exceeding normal physiological synthesis through a mechanism that is separate and distinct levels while excluding pathological causes such as acrome- galy. This is made harder because GH is secreted in a pulsatile manner with exercise and stress being major stimulators of Correspondence: Dr RIG Holt, IDS Building (MP887), Centre Block, GH secretion (Prinz et al., 1983; Savine and So¨nksen, 2000). Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK. Consequently, GH concentrations are often at their highest E-mail: [email protected] Received 25 July 2007; revised 14 November 2007; accepted 3 March 2008; in the immediate post-competition setting when most dope published online 31 March 2008 testing occurs. Recombinant human GH is almost identical GH abuse in sport RIG Holt and PH So¨nksen 543 to pituitary GH, whereas cadaveric GH, which is in plentiful In 2000, Australian discus champion Walter Reiterer claimed supply on the Internet, is indistinguishable from endogenously institutional and supervised usage of GH. With this in mind, produced GH. Blood testing is needed for GH and IGF-I it is interesting to note that 6 months before the Sydney because less than 0.1% is excreted unchanged and even that Olympic Games, 1575 vials of GH were stolen from an is erratic, rendering urine testing unfeasible (Moreira-Andres importer’s warehouse in Sydney. et al., 1993). More recently, Victor Conte, the owner of the Bay Area The review will explore why athletes abuse GH, IGF-I and Laboratory Co-Operative, claimed that he had supplied GH insulin and also the methodology that has been developed to many high-profile American athletes including Tim to catch the cheats. Montgomery and Marion Jones. This admission came after the raid on the Bay Area Laboratory Co-Operative’s head- quarters on 3 September 2003, when evidence of systematic GH abuse in sport doping was found and many of the top names in athletics, baseball and American football were implicated in the Growth hormone was first extracted from human pituitary scandal. Although many have denied taking GH, Tim glands in 1945 (Li et al., 1945). It was shown to promote Montgomery allegedly admitted to taking GH before a US growth in hypopituitary animals and was soon used to Federal grand jury and later faced a 2-year ban for doping restore growth in children with hypopituitarism. How and offences. Conte was imprisoned for 4 months for his role in where GH was first used as a doping agent is unknown, but the scandal (Fainaru-Wada and Williams, 2006). the earliest publication to draw attention to it was Dan The recent conviction of Sylvester Stallone, who was Duchaine’s ‘Underground Steroid handbook’, which caught with GH in his possession on entering Australia, emerged from California in 1982 (Duchaine, 1982). suggests that GH is readily available in athletic and body- Although it contains some fundamental errors, such as the building circles. recommendation and advertisement of animal GH for use in humans, the description of the actions of GH in this article was remarkably accurate and pre-dated adult endocrinology IGF-I abuse in sport experience by about a decade. GH was described as the ‘most expensive, most fashionable and least understood of the new The prevalence of IGF-I abuse is probably much lower than athletic drugs. It has firmly established itself in power-lifting for GH because, unlike GH, there is no readily available and within a few years will be a commonly used drug in all natural source, and therefore all IGF-I is obtained through strength athletics.’ recombinant DNA technology. Two companies currently The most famous case of GH abuse in professional athletics market IGF-I, and these preparations have only recently came to light in 1988 after Ben Johnson won the 100 m gold received approval for use in humans to treat growth failure medal at the Olympic Games in Seoul. He was subsequently in children with severe primary IGF-I deficiency or with GH disqualified after stanazolol was detected in his urine, but at gene deletion who have developed neutralizing GH anti- a later hearing, both he and his coach Charley Francis bodies. The first product is Increlex or recombinant human admitted under oath that he had taken human GH in IGF-I, manufactured by Tercica, and the second product addition to anabolic steroids. manufactured by Insmed is Iplex, which differs from Increlex It is impossible to determine the precise prevalence of GH in that the recombinant human IGF-I is supplied bound to abuse among sportsmen and women, as much of our its major binding protein, IGFBP-3 (Kemp et al., 2006; Kemp, evidence comes from anecdotal reports (McHugh et al., 2007). 2005). Although initially advocated for strength disciplines, Although in relatively short supply, other companies endurance athletes are also attracted to GH’s lipolytic actions make IGF-I for cell culture and other uses, and this material and reduced fat mass; in 1988, a large quantity of GH was could also become available to athletes. The wider avail- found in a team car at the Tour de France. ability of IGF-I, together with an appreciation of the efforts There is evidence that adolescents are using GH. In a to detect GH abuse, is likely to increase its illicit use by survey of two US high schools, 5% of male students admitted athletes, despite being prohibited by the World Anti-Doping to having taken GH and nearly one-third knew someone Agency. who had taken GH (Rickert et al., 1992). Most GH users were unaware of its side effects and reported their first use between 14–15 years of age. Abuse of insulin in sport Growth hormone is an expensive drug and this has led some parents to sell GH prescribed to treat their child’s GH We have only sketchy details about the use of insulin by deficiency on the black market.
Load more

Recommended publications
  • Impact of GH Administration on Athletic Performance in Healthy Young Adults: a Systematic Review and Meta-Analysis of Placebo-Controlled Trials MARK
    Growth Hormone & IGF Research 34 (2017) 38–44 Contents lists available at ScienceDirect Growth Hormone & IGF Research journal homepage: www.elsevier.com/locate/ghir Review Article Impact of GH administration on athletic performance in healthy young adults: A systematic review and meta-analysis of placebo-controlled trials MARK ⁎ Kasper Hermansena, , Mads Bengtsena, Michael Kjærb, Peter Vestergaardc,d, Jens Otto Lunde Jørgensena a Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark b Institute of Sports Medicine, Department of Orthopedic Surgery M, Bispebjerg Hospital and Centre for Healthy Aging, Faculty of Health and Medical Science, University of Copenhagen, Denmark c Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark d Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark ARTICLE INFO ABSTRACT Keywords: Objective: Illicit use of growth hormone (GH) as a performance-enhancing drug among athletes is prevalent, GH although the evidence of such effects in healthy, young subjects is sparse. We therefore performed a meta- Athletic performance analysis of published studies on the effect of GH administration on body composition, substrate metabolism, and Doping athletic performance in healthy, young subjects. Design: The English-language based databases PubMed, EMBASE, and Cochrane Central Register of Controlled Trials were searched, and eligible articles were reviewed in accordance with the PRISMA guidelines. Fifty-four potentially relevant articles were retrieved of which 11 were included in this analysis comprising 254 subjects. Results: Administration of GH significantly increased lean body mass (p < 0.01) and decreased fat mass (p < 0.01). In addition, GH increased the exercising levels of glycerol (p = 0.01) and free fatty acids (p < 0.01), but did not alter the respiratory quotient during exercise (p = 0.30).
    [Show full text]
  • Hormone Abuse in Sports: the Antidoping Perspective
    Asian J Androl 2008; 10 (3): 391–402 DOI: 10.1111/j.1745-7262.2008.00402.x .Review . Hormone abuse in sports: the antidoping perspective Osquel Barroso, Irene Mazzoni, Olivier Rabin Science Department, World Anti-Doping Agency (WADA), Montreal, Quebec H4Z 1B7, Canada Abstract Since ancient times, unethical athletes have attempted to gain an unfair competitive advantage through the use of doping substances. A list of doping substances and methods banned in sports is published yearly by the World Anti- Doping Agency (WADA). A substance or method might be included in the List if it fulfills at least two of the following criteria: enhances sports performance; represents a risk to the athlete’s health; or violates the spirit of sports. This list, constantly updated to reflect new developments in the pharmaceutical industry as well as doping trends, enume- rates the drug types and methods prohibited in and out of competition. Among the substances included are steroidal and peptide hormones and their modulators, stimulants, glucocorticosteroids, β2-agonists, diuretics and masking agents, narcotics, and cannabinoids. Blood doping, tampering, infusions, and gene doping are examples of prohibited methods indicated on the List. From all these, hormones constitute by far the highest number of adverse analytical findings reported by antidoping laboratories. Although to date most are due to anabolic steroids, the advent of molecular biology techniques has made recombinant peptide hormones readily available. These substances are gradu- ally changing the landscape of doping trends. Peptide hormones like erythropoietin (EPO), human growth hormone (hGH), insulin, and insulin-like growth factor I (IGF-I) are presumed to be widely abused for performance enhancement.
    [Show full text]
  • List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
    List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 On March 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) was deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (see section 7002(e)(4)(A) of the Biologics Price Competition and Innovation Act of 2009). To enhance transparency and facilitate planning for the March 23, 2020, transition date, FDA compiled a preliminary list of approved applications for biological products under the FD&C Act that were listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and that would be affected by this transition provision. FDA posted this list on the FDA website in December 2018, and periodically updated this list before the March 23, 2020, transition date. The September 2019 update to this preliminary list added certain administratively closed applications related to approved applications for biological products that were on the December 2018 version of this list. The January 2020 update to the preliminary list reflected a change to the definition of “biological product” made by the Further Consolidated Appropriations Act, 2020, which was enacted on December 20, 2019. Section 605 of this Act further amended the definition of a “biological product” in section 351(i) of the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein.” FDA has provided below a list of each approved application for a biological product under the FD&C Act that was deemed to be a license (i.e., an approved biologics license application (BLA)) for the biological product on March 23, 2020.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Clinical Policy: Mecasermin (Increlex) Reference Number: ERX.SPA.209 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log
    Clinical Policy: Mecasermin (Increlex) Reference Number: ERX.SPA.209 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Mecasermin (Increlex®) is an insulin growth factor-1 (IGF-1) analogue. FDA Approved Indication(s) Increlex is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Limitation(s) of use: Increlex is not a substitute to GH for approved GH indications. Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Increlex is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Severe Primary IGF-1 Deficiency (must meet all): 1. Diagnosis of IGF-1 deficiency growth failure and associated growth failure with one of the following (a or b): a. Severe primary IGF-1 deficiency as defined by all (i through iii): i. Height standard deviation score (SDS) ≤ –3.0; ii. Basal IGF-1 SDS ≤ –3.0; iii. Normal or elevated GH level; b. GH gene deletion with development of neutralizing antibodies to GH; 2. Prescribed by or in consultation with an endocrinologist; 3. Age ≥ 2 and <18 years; 4. At the time of request, member does not have closed epiphyses; 5. Dose does not exceed 0.12 mg/kg twice daily.
    [Show full text]
  • Table of Contents
    Therapeutic systems for Insulin-like growth factor-I Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Julius-Maximilians-Universität Würzburg vorgelegt von Isabel Schultz aus Dahn Würzburg 2015 Eingereicht bei der Fakultät für Chemie und Pharmazie am Gutachter der schriftlichen Arbeit 1. Gutachter: 2. Gutachter: Prüfer des öffentlichen Promotionskolloquiums 1. Prüfer: 2. Prüfer: 3. Prüfer: Datum des öffentlichen Promotionskolloquiums Doktorurkunde ausgehändigt am TABLE OF CONTENTS TABLE OF CONTENTS SUMMARY ............................................................................... 1 ZUSAMMEMFASSUNG .......................................................... 5 CHAPTER I ............................................................................... 9 DRUG DELIVERY OF INSULIN-LIKE GROWTH FACTOR I CHAPTER II ............................................................................ 45 INSULIN-LIKE GROWTH FACTOR-I AEROSOL FORMULATIONS FOR PULMONARY DELIVERY CHAPTER III ........................................................................... 73 PULMONARY INSULIN-LIKE GROWTH FACTOR I DELIVERY FROM TREHALOSE AND SILK-FIBROIN MICROPARTICLES CHAPTER IV ......................................................................... 113 EXPRESSION OF IGF-I MUTANTS CONCLUSION AND OUTLOOK ......................................... 147 DOCUMENTATION OF AUTHORSHIP ............................. 159 CURRICULUM VITAE ......................................................... 163 ACKNOWLEDGMENTS .....................................................
    [Show full text]
  • Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature
    International Journal of Molecular Sciences Review Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature Michaela Plamper, Bettina Gohlke, Felix Schreiner and Joachim Woelfle * Pediatric Endocrinology and Diabetology Division, Children’s Hospital, University of Bonn, Adenauerallee 119, 53113 Bonn, Germany; [email protected] (M.P.); [email protected] (B.G.); [email protected] (F.S.) * Correspondence: Joachim.Woelfl[email protected]; Tel.: +49-228-2873-3223; Fax: +49-228-2873-3472 Received: 8 March 2018; Accepted: 18 April 2018; Published: 24 April 2018 Abstract: Mutations in the insulin receptor (INSR) gene underlie rare severe INSR-related insulin resistance syndromes (SIR), including insulin resistance type A, Rabson–Mendenhall syndrome and Donohue syndrome (DS), with DS representing the most severe form of insulin resistance. Treatment of these cases is challenging, with the majority of DS patients dying within the first two years of life. rhIGF-I (mecasermin) has been reported to improve metabolic control and increase lifespan in DS patients. A case report and literature review were completed. We present a case involving a male patient with DS, harbouring a homozygous mutation in the INSR gene (c.591delC). Initial rhIGF-I application via BID (twice daily) injection was unsatisfactory, but continuous subcutaneous rhIGF-I infusion via an insulin pump improved weight development and diabetes control (HbA1c decreased from 10 to 7.6%). However, our patient died at 22 months of age during the course of a respiratory infection in in Libya. Currently available data in the literature comprising more than 30 treated patients worldwide seem to support a trial of rhIGF-I in SIR.
    [Show full text]
  • What Doctors and Scientists Are Saying About Human Growth Hormone in the Year 2003
    What Doctors and Scientists Are Saying About Human Growth Hormone in the Year 2003. TABLE OF CONTENTS H1 Disclaimer H2 Introduction H3 A String of Successes H3_1 A simple description of the growth hormone system. H3_2 Growth hormone treatment of growth hormone deficiency in children. H3_3 Growth hormone treatment of growth hormone deficiency in adults. H3_4 Growth hormone treatment of children and adults with kidney failure. H3_5 Growth hormone and Prader-Willi syndrome. H3_6 Growth hormone and cystic fibrosis. H3_7 Human growth hormone and Turner Syndrome. H3_8 Growth hormone and severe burns. H3_8_1 The metabolic consequences of severe burns. H3_8_2 The benefits of growth hormone therapy for burns H3_8_3 The disadvantages of growth hormone treatment for burns. H3_8_4 Drug combinations may bring burn therapy progress. H3_9 Growth hormone can reduce wasting in critically ill patients. H3_10 The effects of axis hormones on skin and wound healing. H3_11 Growth hormone therapy in HIV-infected patients. H3_12 Conclusions about hGH-responsive medical conditions. H4 A Promising Disappointment: Growth Hormone and Ageing. H4_1 Ageing, bone strength and growth hormone. H4_2 Age, muscle loss (sarcopenia) and growth hormone. H4_2_1 A description of age-related sarcopenia H4_2_2 The causes of age-related sarcopenia. H4_2_3 Exercise is the best antidote to sarcopenia. H4_2_4 Growth hormone may modestly increase muscular strength in the elderly. H4_2_5 Growth hormone increases lean mass, but the benefit is uncertain. H4_2_6 Innervation changes may enhance muscle strength. H4_2_7 Growth hormone resistance. H4_2_8 Exercise induces growth hormone. H4_2_9 Obesity decreases growth hormone secretion. H4_2_10 Locally produced IGF-I may dominate age-related sarcopenia H4_2_11 GH inducers can strengthen muscles in the elderly.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Proefschrift Door
    STRIKING THE RIGHT BALANCE Effectiveness of Anti-Doping Policies ZOEKEN NAAR HET JUISTE EVENWICHT Effectiviteit van het anti-dopingbeleid (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op vrijdag 18 november 2016 des middags te 2.30 uur door Olivier Matthijs de Hon geboren op 3 september 1972 te Amsterdam Promotor: Prof.dr. M. van Bottenburg Dit proefschrift werd mede mogelijk gemaakt met financiële steun van het Ministerie van Volksgezondheid, Welzijn en Sport. In mooie herinnering aan Julie, die altijd overal bij zal zijn In loving memory of Julie, who will always be present at all occasions Assessment Committee: Prof.dr. F.J.G. Backx (Utrecht University) Prof.dr. J.P.P.E.F. Boselie (Utrecht University) Prof.dr. J. Hoberman (University of Texas at Austin) Prof.dr. M.J. McNamee (Swansea University) Prof.dr. V. Møller (Aarhus University) On the day of thesis defence the Doctoral Examination Committee will also include: Prof.dr. M. van den Berg (Utrecht University) Prof.dr. M. Olfers (VU University Amsterdam) Prof.dr. S.H. Backhouse (Leeds Beckett University) The time to write this thesis was partially made available by means of a grant from the Dutch Ministry of Health, Welfare, and Sports. Printing this thesis has been financially enabled by Anti-Doping Authority Netherlands, also known as ‘Dopingautoriteit’. All views presented in this thesis are solely the individual views of the author and are by no means official policy statements of any organisation.
    [Show full text]
  • From Gene to Gender - What We’Ve Learned and What We Need to Learn - New Prospects in DSD Research
    3rd International Symposium on Disorders of Sex Development 20 – 22 May 2011 · Universität zu Lübeck Programme & Abstracts From Gene to Gender - What we’ve learned and what we need to learn - New Prospects in DSD Research Sessions on Genetics, Hormones & Action, Morphologic Variation in DSD and Clinical Aspects · Round Table · Poster Session and Oral Sessions 20 – 22 May 2011, Lübeck, Germany 1 Contents Contents...................................................................................................................................1 Welcome Remarks ...................................................................................................................3 About EuroDSD........................................................................................................................4 General Information..................................................................................................................5 Scientific Programme ...............................................................................................................6 Social Programme....................................................................................................................9 Speakers’ List.........................................................................................................................10 Poster Presentation................................................................................................................12 Abstracts Keynote Lectures ...................................................................................................15
    [Show full text]
  • Product Monograph Including Patient Medication Information
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrINCRELEX® mecasermin injection 10 mg/mL (40 mg/4mL) Recombinant DNA-derived human insulin-like growth factor-1 (IGF-1) Ipsen Biopharmaceuticals Canada Inc. Date of Revision: 5060 Spectrum Way, Suite 505 December 17, 2020 Mississauga, ON L4W 5N5 Submission Control No: 235023 INCRELEX is a registered trademark of Ipsen Biopharmaceuticals, Inc. TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 3 1 INDICATIONS ................................................................................................................. 3 1.1 Pediatrics ............................................................................................................... 3 2 CONTRAINDICATIONS .................................................................................................. 3 3 DOSAGE AND ADMINISTRATION ................................................................................ 3 3.1 Dosing Considerations ........................................................................................... 3 3.2 Recommended Dose and Dosage Adjustment ....................................................... 4 3.3 Administration ........................................................................................................ 4 3.4 Missed Dose .........................................................................................................
    [Show full text]